Physician profile
Robert A Johnson
NPI 1205858024
$5,988.03
in general payments reported to CMS, 2019-2025
20 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,092 · 2020: $1,059 · 2021: $1,364 · 2022: $1,424 · 2023: $794 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.31 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,025.31 | 2019-2025 | Breztri, Symbicort, Airsupra |
| Glaxosmithkline, LLC. | $1,315.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,108.18 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $314.10 | 2019-2025 | Dupixent |
| Pfizer INC. | $268.80 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $259.82 | 2021-2023 | Acthar |
| Genzyme Corporation | $195.64 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $126.50 | 2021-2023 | Uptravi, Opsumit |
| Philips North America LLC | $68.93 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.93 | 2020-2023 | Aralast |
| Mylan Specialty L.P. | $43.07 | 2019 | |
| Sunovion Pharmaceuticals INC. | $36.55 | 2019 | |
| Exact Sciences Corporation | $35.53 | 2023-2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $26.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.41 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.11 | 2025 | Tezspire |
| Lilly USA, LLC | $13.98 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $13.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.35 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.